MIST Milestone Pharmaceuticals

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a corporate panel discussion at the TD Cowen 44th Annual Health Care Conference on March 5, 2024, at 10:30am ET.

The webcast is available to watch both live and replay for approximately 90 days following the presentation in the News & Events section of Milestone's website.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat highly symptomatic episodic attacks associated with PSVT and AFib-RVR.

Contact:

Kim Fox, Vice President, Communications

 

704-803-9295

Investor Relations

Chris Calabrese

Kevin Gardner



EN
29/02/2024

Underlying

MISTMilestone Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Milestone Pharmaceuticals

 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results...

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update – NDA for etripamil in PSVT resubmitted in 1Q 2024– Cash resources as of March 31, 2024 expected to fund operations into 2026– Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR is progressing MONTREAL and CHARLOTTE, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the first quarter ended March 31, 2024 and provided a regulatory and corporate update. “We’re currently on track...

7h 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone® Pharmaceuticals Announces Data Presentations on Etripamil a...

Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024 MONTREAL and CHARLOTTE, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced upcoming data presentations on etripamil at being held in Atlanta, GA on May 5-8, 2024, the 2024 in Boston, MA, on May 15, 2024, and the Annual meeting of the Heart Rhythm Society, , in ...

May 2, 2024 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone® Pharmaceuticals to Present Data on Etripamil at the Prevent...

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium MONTREAL and CHARLOTTE, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at the 30th Annual Cardiovascular Nursing Symposium held by the Preventive Cardiovascular Nurses Association on April 18-20th in Orlando, FL. The posters will be available following the embargo at . ...

April 17, 2024 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Pati...

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting Data from this large safety-trial also published in The Journal of the American College of Cardiology MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced new clinical data demonstrating real-world application of etripamil,...

April 8, 2024 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healt...

Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference MONTREAL and CHARLOTTE, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will deliver a company presentation at the 23rd Annual Needham Virtual Healthcare Conference on April 10, 2024 at 8:45 am ET. The webcast is available to watch both live and replay for approximately 90 days following the presentation in the News & Events section of Milestone’s website. About Milestone PharmaceuticalsMilestone Pharmaceu...

April 3, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch